Study guide

10.1 Biostatistics and Critical Appraisal of Clinical Literature

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

10.1 Biostatistics and Critical Appraisal of Clinical Literature

Key Takeaways Explain This Topic AI

Variable measurement scales dictate statistical test selection: nominal and ordinal data require non-parametric tests, while continuous normally distributed data utilize parametric tests such as Student's t-test and ANOVA.

A p-value below 0.05 denotes statistical significance but does not confirm clinical relevance, which must be judged against the Minimal Clinically Important Difference (MCID).

Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT = 1 / ARR) quantify true therapeutic benefit, with NNT always rounded up to the nearest whole integer.

A 95% confidence interval spanning zero indicates non-significance for difference metrics (ARR, mean difference), whereas spanning 1.0 indicates non-significance for ratio metrics (RR, OR, HR).

Intention-to-Treat (ITT) analysis includes all randomized patients according to their initial allocation, preserving baseline prognostic balance and avoiding the overoptimistic bias of per-protocol analysis.

Last updated: August 2026

10.1 Biostatistics and Critical Appraisal of Clinical Literature

Exam Focus: The PEBC Pharmacist Evaluating Examination requires candidates to critically appraise biomedical literature, interpret epidemiological data, and select appropriate statistical tests. Candidates must master calculations for Absolute Risk Reduction ( A R R ARR A RR ), Relative Risk Reduction ( R R R RRR RRR ), Number Needed to Treat ( N N T NNT NNT ), and Number Needed to Harm ( N N H NNH NN H ), evaluate confidence intervals, identify trial biases, and understand Intention-to-Treat ( I T T ITT I TT ) versus per-protocol methodologies.

Data Types and Measurement Scales

Selecting the appropriate statistical test begins with correctly identifying the scale of measurement of the variables under study.

Variable Scale Definition & Properties Mathematical Operations Clinical Examples in Pharmacy

Nominal (Categorical) Unordered, mutually exclusive categories; qualitative classification with no inherent ranking. Frequency counts, modes, proportions, percentages. Sex (male/female), mortality status (alive/dead), smoking status, blood type, presence of adverse drug event (yes/no).

Ordinal Categorical variables with an inherent, logical order or rank, but the intervals between ranks are unequal or non-quantifiable. Medians, percentiles, rank-order correlations. NYHA Heart Failure Classification (Class I-IV), Visual Analog Pain Scale (0-10), Likert survey responses, cancer stages.

Continuous: Interval Quantitative, ordered numerical data with constant, equal distances between units, but with an arbitrary (non-absolute) zero point. Addition, subtraction, mean, standard deviation. Temperature in degrees Celsius ( ∘ C ^\circ\text{C} ∘ C ) or Fahrenheit ( ∘ F ^\circ\text{F} ∘ F ); zero does not mean absence of temperature.

Continuous: Ratio Quantitative continuous numerical data with equal intervals and a true, absolute zero point representing the total absence of the variable. Addition, subtraction, multiplication, division, ratios. Blood pressure (mmHg), serum creatinine ( μ mol/L \mu\text{mol/L} μ mol/L ), weight (kg), hemoglobin A1c (%), medication dose (mg), creatinine clearance.

Descriptive Statistics: Central Tendency and Dispersion

Descriptive statistics summarize and describe the characteristics of a specific dataset without drawing generalized conclusions about the broader population.

1. Measures of Central Tendency

Mean (Arithmetic Average): The sum of all values divided by the total number of observations ( n n n ). Parametric measure; highly sensitive to extreme outliers and skewed data.

Median: The middle observation when data are sorted in ascending order (the 50th percentile). Non-parametric measure; robust to extreme values and preferred for skewed or ordinal datasets.

Mode: The most frequently occurring value in a dataset. Useful for nominal categorical data.

2. Measures of Dispersion (Spread)

Standard Deviation ( S D SD S D ): Quantifies the degree of dispersion or spread of individual data points around the sample mean in a normally distributed dataset. In a standard normal distribution:

Mean ± 1 S D \text{Mean} \pm 1\,SD Mean ± 1 S D encompasses approximately 68.2% of observations.

Mean ± 2 S D \text{Mean} \pm 2\,SD Mean ± 2 S D encompasses approximately 95.4% of observations ( ± 1.96 S D \pm 1.96\,SD ± 1.96 S D covers exactly 95.0% ).

Mean ± 3 S D \text{Mean} \pm 3\,SD Mean ± 3 S D encompasses approximately 99.7% of observations.

Interquartile Range ( I Q R IQR I QR ): The distance between the 25th percentile ( Q 1 Q_1 Q 1 ​ ) and the 75th percentile ( Q 3 Q_3 Q 3 ​ ), representing the middle 50% of observations ( I Q R = Q 3 − Q 1 IQR = Q_3 - Q_1 I QR = Q 3 ​ − Q 1 ​ ). Reported alongside the median for skewed or ordinal distributions.

Standard Error of the Mean ( S E M SEM SEM ): Measures the precision with which the sample mean estimates the true population mean, calculated as: SEM = S D n \text{SEM} = \frac{SD}{\sqrt{n}} SEM = n ​ S D ​ S E M SEM SEM is always smaller than the S D SD S D and should never be used as a substitute for S D SD S D to describe data variability. +-------------------------------------------------------------------------+

  • | DATA DISTRIBUTION PATTERNS |
  • +-------------------------------------------------------------------------+
  • | 1. NORMAL (GAUSSIAN) DISTRIBUTION: Symmetrical, Bell-Shaped |
  • | Mean = Median = Mode |
  • | |
  • | 2. POSITIVELY SKEWED (RIGHT-SKEWED): Tail stretches to the right |
  • | Mean > Median > Mode (e.g., Length of hospital stay, drug costs) |
  • | |
  • | 3. NEGATIVELY SKEWED (LEFT-SKEWED): Tail stretches to the left |
  • | Mean < Median < Mode (e.g., Age at natural death in Canada) |
  • +-------------------------------------------------------------------------+
  • Inferential Statistics, Hypothesis Testing, and Error Types

Inferential statistics use sample data to make generalized inferences about an underlying target population.

Formulating Hypotheses

Null Hypothesis ( H 0 H_0 H 0 ​ ): States that there is no true difference, effect, or association between the study groups (any observed difference is due purely to random sampling variation).

Alternative Hypothesis ( H a H_a H a ​ or H 1 H_1 H 1 ​ ): States that there is a true difference or effect between the treatment groups.

Type I and Type II Errors

Statistical Decision True Population Reality: H 0 H_0 H 0 ​ is True (No Effect) True Population Reality: H 0 H_0 H 0 ​ is False (True Effect Exists)

Reject H 0 H_0 H 0 ​ (Conclude Significant Effect) Type I Error ( α \alpha α ) ; False Positive (Concluded a drug works when it does not). Correct Decision ( 1 − β 1 - \beta 1 − β ) ; Statistical Power (Detected a real effect).

Fail to Reject H 0 H_0 H 0 ​ (Conclude No Significant Effect) Correct Decision ( 1 − α 1 - \alpha 1 − α ) ; True Negative (Correctly found no difference). Type II Error ( β \beta β ) ; False Negative (Missed a real therapeutic effect).

Alpha ( α \alpha α ): The probability of committing a Type I error (conventionally set a priori at α = 0.05 \alpha = 0.05 α = 0.05 ).

Beta ( β \beta β ): The probability of committing a Type II error (conventionally set at β = 0.10 \beta = 0.10 β = 0.10 to 0.20 0.20 0.20 ).

Statistical Power ( 1 − β 1 - \beta 1 − β ): The probability of correctly rejecting the null hypothesis when a true clinical difference exists (typically targeted at ≥ 80 % \ge 80\% ≥ 80% to 90 % 90\% 90% ). Power increases with larger sample sizes ( n n n ), larger effect sizes, lower data variance, and higher alpha thresholds.

The p-value versus Clinical Significance

p-value: The probability of obtaining a result as extreme as, or more extreme than, the observed trial result, assuming the null hypothesis is true. A p < 0.05 p < 0.05 p < 0.05 indicates statistical significance, meaning random chance is an unlikely explanation for the observed difference.

Clinical Significance: Refers to the practical, real-world clinical importance of the treatment effect. A statistically significant reduction in systolic blood pressure of 0.8 mmHg 0.8\text{ mmHg} 0.8 mmHg ( p = 0.002 p = 0.002 p = 0.002 ) across 50,000 trial participants may lack clinical importance if the Minimal Clinically Important Difference (MCID) is 5.0 mmHg 5.0\text{ mmHg} 5.0 mmHg .

95% Confidence Intervals (95% CI)

A 95% Confidence Interval provides a range of values within which the true population parameter is expected to fall with 95% certainty. The width of the interval indicates precision: narrower intervals reflect larger sample sizes and greater precision.

For Difference Metrics (Mean Difference, A R R ARR A RR , Absolute Risk Increase): If the 95% CI crosses or includes 0.0 , the result is not statistically significant ( p ≥ 0.05 p \ge 0.05 p ≥ 0.05 ).

For Ratio Metrics (Relative Risk, Odds Ratio, Hazard Ratio): If the 95% CI crosses or includes 1.0 , the result is not statistically significant ( p ≥ 0.05 p \ge 0.05 p ≥ 0.05 ).

Statistical Test Selection Matrix

Choosing the correct inferential statistical test depends on the type of data, distribution normality, number of groups, and whether samples are independent or paired.

Number of Groups Data Type / Distribution Independent Samples Test Paired / Dependent Samples Test

2 Groups Continuous (Normal / Parametric) Independent Student's t-test Paired Student's t-test (e.g., pre/post)

2 Groups Continuous (Skewed) or Ordinal Mann-Whitney U test (Wilcoxon rank-sum) Wilcoxon signed-rank test

≥ 3 \ge 3 ≥ 3 Groups Continuous (Normal / Parametric) One-Way ANOVA (Analysis of Variance) Repeated Measures ANOVA

≥ 3 \ge 3 ≥ 3 Groups Continuous (Skewed) or Ordinal Kruskal-Wallis test Friedman test

Categorical Counts Nominal Proportions (Large cells ≥ 5 \ge 5 ≥ 5 ) Chi-Square ( χ 2 \chi^2 χ 2 ) Test of Independence McNemar test (paired binary)

  • Categorical Counts Nominal Proportions (Small cells < 5 < 5 < 5 ) Fisher's Exact Test McNemar test
  • Clinical Trial Risk and Effect Size Calculations

Evaluating the magnitude of benefit or harm requires transforming raw trial counts into standardized epidemiological metrics using a standard 2 × 2 2 \times 2 2 × 2 contingency table. +-------------------------------------------------------------------------+

  • | 2 x 2 CONTINGENCY TABLE |
  • +-------------------------------------------------------------------------+
  • | | Disease / Event Present | Disease / Event Absent |
  • | ------------------- | :---------------------: | :---------------------: |
  • | Treatment Group | a | b |
  • | Control Group | c | d |
  • +-------------------------------------------------------------------------+
  • 1. Event Rates
  • Experimental Event Rate ( E E R EER EER ): E E R = a a + b EER = \frac{a}{a + b} EER = a + b a ​
  • Control Event Rate ( C E R CER CER ): C E R = c c + d CER = \frac{c}{c + d} CER = c + d c ​
  • 2. Relative Risk ( R R RR RR ) and Relative Risk Reduction ( R R R RRR RRR )

Relative Risk / Risk Ratio ( R R RR RR ): The ratio of the risk of an event occurring in the experimental group compared to the control group: R R = E E R C E R RR = \frac{EER}{CER} RR = CER EER ​

R R = 1.0 RR = 1.0 RR = 1.0 : No difference in risk between groups.

R R < 1.0 RR < 1.0 RR < 1.0 : Experimental intervention reduces risk (protective effect).

R R > 1.0 RR > 1.0 RR > 1.0 : Experimental intervention increases risk (harmful effect).

Relative Risk Reduction ( R R R RRR RRR ): The proportional reduction in event rates attributable to the intervention relative to baseline risk: R R R = C E R − E E R C E R = 1 − R R RRR = \frac{CER - EER}{CER} = 1 - RR RRR = CER CER − EER ​ = 1 − RR

3. Absolute Risk Reduction ( A R R ARR A RR ) and Number Needed to Treat ( N N T NNT NNT )

Absolute Risk Reduction ( A R R ARR A RR ): The absolute arithmetic difference in event rates between control and treatment groups: A R R = C E R − E E R ARR = CER - EER A RR = CER − EER

Number Needed to Treat ( N N T NNT NNT ): The number of patients who must be treated with the intervention for a specified duration to prevent one additional adverse clinical event: N N T = 1 A R R = 1 C E R − E E R NNT = \frac{1}{ARR} = \frac{1}{CER - EER} NNT = A RR 1 ​ = CER − EER 1 ​

Rounding Rule for NNT: Always round UP to the next whole integer (e.g., N N T = 14.2 → 15 NNT = 14.2 \rightarrow 15 NNT = 14.2 → 15 ).

4. Absolute Risk Increase ( A R I ARI A R I ) and Number Needed to Harm ( N N H NNH NN H )

Absolute Risk Increase ( A R I ARI A R I ): When an intervention increases the rate of an adverse event ( E E R > C E R EER > CER EER > CER ): A R I = E E R − C E R ARI = EER - CER A R I = EER − CER

Number Needed to Harm ( N N H NNH NN H ): The number of patients exposed to the drug to cause one additional adverse event: N N H = 1 A R I = 1 E E R − C E R NNH = \frac{1}{ARI} = \frac{1}{EER - CER} NN H = A R I 1 ​ = EER − CER 1 ​

Rounding Rule for NNH: Always round DOWN to the nearest whole integer for conservative risk assessment (e.g., N N H = 22.8 → 22 NNH = 22.8 \rightarrow 22 NN H = 22.8 → 22 ).

5. Odds Ratio ( O R OR OR ) and Hazard Ratio ( H R HR H R )

Odds Ratio ( O R OR OR ): Used primarily in retrospective case-control studies where baseline incidence rates cannot be calculated: O R = Odds of exposure in cases Odds of exposure in controls = a / c b / d = a × d b × c OR = \frac{\text{Odds of exposure in cases}}{\text{Odds of exposure in controls}} = \frac{a / c}{b / d} = \frac{a \times d}{b \times c} OR = Odds of exposure in controls Odds of exposure in cases ​ = b / d a / c ​ = b × c a × d ​

Hazard Ratio ( H R HR H R ): Derived from Cox proportional hazards survival regression models; represents the relative likelihood of an event occurring at any specific point in time across longitudinal follow-up. +-------------------------------------------------------------------------+

  • | WORKED CLINICAL CALCULATION EXAMPLE |
  • +-------------------------------------------------------------------------+
  • | Trial: SGLT2 inhibitor vs Placebo for HF hospitalizations over 2 years |
  • | - Placebo (Control): 120 events out of 1000 patients (CER = 12% = 0.12)|
  • | - SGLT2i (Treatment): 72 events out of 1000 patients (EER = 7.2%= 0.072)|
  • | |
  • | CALCULATIONS: |
  • | - RR = 0.072 / 0.12 = 0.60 |
  • | - RRR = (0.12 - 0.072) / 0.12 = 0.048 / 0.12 = 0.40 (40% reduction) |
  • | - ARR = 0.12 - 0.072 = 0.048 (4.8% absolute reduction) |
  • | - NNT = 1 / 0.048 = 20.83 --> Round UP to 21 |
  • | Conclusion: Treating 21 heart failure patients with the SGLT2i for 2 |
  • | years prevents 1 hospital admission. |
  • +-------------------------------------------------------------------------+
  • Critical Appraisal of Clinical Trial Methodologies
  • Hierarchy of Evidence
  • Systematic reviews and Meta-analyses of randomized controlled trials (RCTs)
  • High-quality double-blind Randomized Controlled Trials (RCTs)
  • Prospective Cohort Studies
  • Retrospective Case-Control Studies
  • Cross-Sectional Surveys
  • Case Series and Case Reports
  • Expert Opinion and in vitro bench research
  • Randomization and Blinding

Randomization: Balances known and unknown baseline prognostic factors between groups (simple, block, or stratified randomization).

Allocation Concealment: Prevents investigators from predicting or influencing group assignments prior to enrollment (e.g., central computerized assignment, sealed opaque envelopes).

Blinding (Masking): Prevents performance and ascertainment bias:

Single-blind: Patient is unaware of assignment.

Double-blind: Patient and treating clinicians/outcome assessors are unaware.

Triple-blind: Patient, clinicians, outcome assessors, and data analysts/biostatisticians are all blinded.

Intention-to-Treat ( I T T ITT I TT ) versus Per-Protocol ( P P PP PP ) +-------------------------------------------------------------------------+

  • | ANALYSIS POPULATION METHODOLOGIES |
  • +-------------------------------------------------------------------------+
  • | 1. INTENTION-TO-TREAT (ITT): |
  • | - Analyzes all randomized subjects in their assigned treatment groups, |
  • | regardless of protocol deviations, non-adherence, or early dropout. |
  • | - Preserves baseline randomization balance and prevents attrition bias. |
  • | - Reflects real-world clinical effectiveness (conservative estimate). |
  • | |
  • | 2. PER-PROTOCOL (PP) / AS-TREATED: |
  • | - Analyzes only subjects who completed the prescribed trial protocol |
  • | with strict compliance and no major deviations. |
  • | - Measures maximal pharmacological efficacy under ideal conditions. |
  • | - Prone to attrition bias; breaks baseline prognostic randomization. |
  • +-------------------------------------------------------------------------+
  • Trial Design Frameworks

Superiority Trials: Designed to prove that a new intervention is clinically superior to a placebo or active control.

Non-Inferiority Trials: Designed to establish that a new treatment is not clinically worse than an active standard-of-care comparator by more than a predefined margin (the non-inferiority margin, Δ \Delta Δ ). Commonly utilized when a new drug offers secondary benefits (e.g., oral dosing vs IV, reduced toxicity, improved tolerability, lower cost).

Common Methodological Biases

Selection Bias: Systematic differences between baseline characteristics of participants enrolled versus those not enrolled.

Recall Bias: Differential recall of past exposures between diseased cases and healthy controls in retrospective studies.

Publication Bias: Tendency for journals to publish positive trials over negative/neutral studies; evaluated visually using funnel plots (asymmetry indicates publication bias) and Egger tests.

Confounding by Indication: Occurs in observational studies when the clinical indication for prescribing a drug is itself independently associated with the adverse outcome.